Sarah Ketterer
Causeway Capital Management
Sarah Ketterer Zimmer Biomet Holdings Inc stake
total: 372
Causeway Capital Management ZBH trades
- Total transactions:
- 26
- New positions:
- 2
- Sold out:
- 1
- Added:
- 12
- Reduced:
- 11
- Held since:
- 2021 Q4
- Held for:
- 19 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Sarah Ketterer holds 788,810 Zimmer Biomet Holdings Inc (ZBH) shares with a market value of roughly $67.91M accounting for 0.74% of the overall portfolio. To date, the estimated cost basis is nearly $114.88 for "buy" trades and estimated average "sell" price is $115.48. Causeway Capital Management first purchased ZBH in 2018 Q2, initially acquiring about 1.19M shares. Sarah Ketterer later completely sold out the position and invested in Zimmer Biomet Holdings Inc again in 2021 Q4. Since the initial investment in Zimmer Biomet Holdings Inc (ZBH), Causeway Capital Management has made 25 more transactions.
When did Sarah Ketterer buy Zimmer Biomet Holdings Inc (ZBH)?
Sarah Ketterer first invested in Zimmer Biomet Holdings Inc (ZBH) in 2018 Q2 at the reported quarter-end price of $111.44 per share.
What's the cost basis of Causeway Capital Management's ZBH stake?
The estimated cost basis for Zimmer Biomet Holdings Inc (ZBH) stake is around $114.88 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $114.88
- Weighted AVG sell price:
- $115.48
Sarah Ketterer's historical trades in Zimmer Biomet Holdings Inc
26 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.74%
|
788,810
|
$86.09
|
$67,908,650
|
-2.39% (-19,300)
|
-0.02%
|
|
2026 Q1
|
0.90%
|
808,110
|
$90.42
|
$73,069,309
|
+10.93% (+79,612)
|
+0.09%
|
|
2025 Q4
|
0.90%
|
728,498
|
$89.92
|
$65,506,589
|
+25.22% (+146,719)
|
+0.18%
|
|
2025 Q3
|
0.76%
|
581,779
|
$98.50
|
$57,305,179
|
+0.61% (+3,541)
|
+0%
|
|
2025 Q2
|
0.83%
|
578,238
|
$91.21
|
$52,741,023
|
-28.21% (-227,271)
|
-0.43%
|
|
2025 Q1
|
1.91%
|
805,509
|
$113.18
|
$91,167,554
|
+4.62% (+35,577)
|
+0.08%
|
|
2024 Q4
|
1.85%
|
769,932
|
$105.63
|
$81,327,915
|
-3.07% (-24,356)
|
-0.06%
|
|
2024 Q3
|
2.11%
|
794,288
|
$107.95
|
$85,743,364
|
+20.20% (+133,482)
|
+0.35%
|
|
2024 Q2
|
1.96%
|
660,806
|
$108.53
|
$71,717,198
|
+30.53% (+154,551)
|
+0.46%
|
|
2024 Q1
|
1.75%
|
506,255
|
$132.05
|
$66,849,961
|
-10.34% (-58,414)
|
-0.2%
|
|
2023 Q4
|
1.75%
|
$121.70
|
+39.13% (+158,806)
|
|||
|
2023 Q3
|
1.20%
|
$112.22
|
+79.57% (+179,845)
|
|||
|
2023 Q2
|
0.87%
|
$145.60
|
-46.68% (-197,872)
|
|||
|
2023 Q1
|
1.31%
|
$129.20
|
-1.87% (-8,072)
|
|||
|
2022 Q4
|
1.60%
|
$127.50
|
-5.93% (-27,247)
|
|||
|
2022 Q3
|
1.35%
|
$104.55
|
-11.99% (-62,564)
|
|||
|
2022 Q2
|
1.37%
|
$105.06
|
-6.19% (-34,425)
|
|||
|
2022 Q1
|
1.70%
|
$127.90
|
+129.96% (+314,335)
|
|||
|
2021 Q4
|
0.68%
|
$127.04
|
new
|
|||
|
2019 Q4
|
0.00%
|
$137.27
|
-100% (-1,009,417)
|
|||
|
2019 Q3
|
1.65%
|
$137.27
|
-8.70% (-96,248)
|
|||
|
2019 Q2
|
1.42%
|
$117.74
|
+5.43% (+56,992)
|
|||
|
2019 Q1
|
1.35%
|
$127.70
|
-20.28% (-266,790)
|
|||
|
2018 Q4
|
1.63%
|
$103.72
|
+8.50% (+103,001)
|
|||
|
2018 Q3
|
1.60%
|
$131.47
|
+2.07% (+24,599)
|
|||
|
2018 Q2
|
1.34%
|
$111.44
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.